Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.AVTE · Entity 4757 | SEE REMARKS | July 31, 2024 | August 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date July 31, 2024 · Filed August 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,252 |
Ending reported balance
After 2024-08-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-07-31 · Exercise / conversion · Acquired 11,454 · Balance 12,745 Row 2 · 2024-08-01 · Exercise / conversion · Acquired 1,507 · Balance 14,252 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 0 |
Reported balance
After 2024-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-07-31 · Exercise / conversion · Disposed 906 · Balance 0 F1: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 1,507 |
Reported balance
After 2024-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-07-31 · Exercise / conversion · Disposed 10,548 · Balance 1,507 F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-01 · Exercise / conversion · Disposed 1,507 · Balance 0 F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2022 Filed Sep 14, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 272 | $18.77 | $5,104.90 |
DisclosureSEC source: 0001415889-22-009612 · form4-09142022_050901.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.72 to $18.86, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,976 | $18.26 | $36,086.90 |
DisclosureSEC source: 0001415889-22-009612 · form4-09142022_050901.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.595 to $18.54, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 5,272 | $16.90 | $89,114.72 |
DisclosureSEC source: 0001415889-22-009612 · form4-09142022_050901.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,248 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.59 to $17.58, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 7,520 | $2.14 | $16,092.80 |
DisclosureSEC source: 0001415889-22-009612 · form4-09142022_050901.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,462 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001493152-22-025660 · ownership.xml · derivative · entry 11 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,420 Underlying: Common Stock · 4,462 shares Expires 2031-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F8 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 258 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-025660 · ownership.xml · derivative · entry 10 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,488 Underlying: Common Stock · 258 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 176 | $18.54 | $3,262.32 |
DisclosureSEC source: 0001493152-22-025660 · ownership.xml · nonDerivative · entry 7 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.07 to $18.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4,544 | $17.50 | $79,540.45 |
DisclosureSEC source: 0001493152-22-025660 · ownership.xml · nonDerivative · entry 6 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.06 to $18.06, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 4,462 | $2.14 | $9,548.68 |
DisclosureSEC source: 0001493152-22-025660 · ownership.xml · nonDerivative · entry 5 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 258 | $1.74 | $448.92 |
DisclosureSEC source: 0001493152-22-025660 · ownership.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,472 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-025660 · ownership.xml · derivative · entry 9 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,656 Underlying: Common Stock · 2,472 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 648 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-025660 · ownership.xml · derivative · entry 8 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,746 Underlying: Common Stock · 648 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 629 | $18.42 | $11,588.32 |
DisclosureSEC source: 0001493152-22-025660 · ownership.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.40 to $18.505, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,491 | $18.14 | $45,193.22 |
DisclosureSEC source: 0001493152-22-025660 · ownership.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 629 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.39 to $18.385, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 3,120 | $1.74 | $5,428.80 |
DisclosureSEC source: 0001493152-22-025660 · ownership.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| September 07, 2022 Filed Sep 8, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,220 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-025399 · ownership.xml · derivative · entry 9 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,128 Underlying: Common Stock · 8,220 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| September 07, 2022 Filed Sep 8, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,658 | $18.42 | $67,386.21 |
DisclosureSEC source: 0001493152-22-025399 · ownership.xml · nonDerivative · entry 7 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.345 to $18.625, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 07, 2022 Filed Sep 8, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4.562 | $18.12 | $82.65 |
DisclosureSEC source: 0001493152-22-025399 · ownership.xml · nonDerivative · entry 6 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,658 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.32 to $18.32, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 07, 2022 Filed Sep 8, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 8,220 | $1.74 | $14,302.80 |
DisclosureSEC source: 0001493152-22-025399 · ownership.xml · nonDerivative · entry 5 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,166 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-025399 · ownership.xml · derivative · entry 8 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,348 Underlying: Common Stock · 9,166 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 606 | $19.78 | $11,984.38 |
DisclosureSEC source: 0001493152-22-025399 · ownership.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.595 to $20.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4,138 | $18.98 | $78,546.27 |
DisclosureSEC source: 0001493152-22-025399 · ownership.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.57 to $19.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4,422 | $17.94 | $79,345.27 |
DisclosureSEC source: 0001493152-22-025399 · ownership.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,744 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.56 to $18.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 17:30 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 9,166 | $1.74 | $15,948.84 |
DisclosureSEC source: 0001493152-22-025399 · ownership.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,811 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-023472 · ownership.xml · derivative · entry 6 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,514 Underlying: Common Stock · 17,811 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,189 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-023472 · ownership.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,394 Underlying: Common Stock · 3,189 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,451 | $24.10 | $83,173.59 |
DisclosureSEC source: 0001493152-22-023472 · ownership.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.95 to $24.57, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 7,074 | $23.29 | $164,724.46 |
DisclosureSEC source: 0001493152-22-023472 · ownership.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,451 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.94 to $23.94, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 10,475 | $22.44 | $235,033.86 |
DisclosureSEC source: 0001493152-22-023472 · ownership.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,525 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.92 to $22.915, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 21,000 | $1.74 | $36,540.00 |
DisclosureSEC source: 0001493152-22-023472 · ownership.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,347 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-022415 · ownership.xml · derivative · entry 8 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,583 Underlying: Common Stock · 1,347 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 79 | $24.55 | $1,939.45 |
DisclosureSEC source: 0001493152-22-022415 · ownership.xml · nonDerivative · entry 6 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,268 | $23.89 | $30,292.39 |
DisclosureSEC source: 0001493152-22-022415 · ownership.xml · nonDerivative · entry 5 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.47 to $24.26, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,347 | $1.74 | $2,343.78 |
DisclosureSEC source: 0001493152-22-022415 · ownership.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,720 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-022415 · ownership.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,930 Underlying: Common Stock · 12,720 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 780 | $24.48 | $19,095.96 |
DisclosureSEC source: 0001493152-22-022415 · ownership.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.435 to $25.15, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 11,940 | $24.06 | $287,270.43 |
DisclosureSEC source: 0001493152-22-022415 · ownership.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 780 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.43 to $24.40, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 12,720 | $1.74 | $22,132.80 |
DisclosureSEC source: 0001493152-22-022415 · ownership.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,700 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-021919 · ownership.xml · derivative · entry 8 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,650 Underlying: Common Stock · 8,700 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,791 | $24.52 | $68,436.44 |
DisclosureSEC source: 0001493152-22-021919 · ownership.xml · nonDerivative · entry 6 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.345 to $24.70, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 5,909 | $23.84 | $140,888.88 |
DisclosureSEC source: 0001493152-22-021919 · ownership.xml · nonDerivative · entry 5 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,791 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.34 to $24.34, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 8,700 | $1.74 | $15,138.00 |
DisclosureSEC source: 0001493152-22-021919 · ownership.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,943 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-22-021919 · ownership.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,350 Underlying: Common Stock · 6,943 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,954 | $24.94 | $73,678.37 |
DisclosureSEC source: 0001493152-22-021919 · ownership.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.81 to $25.43, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,989 | $24.39 | $97,283.33 |
DisclosureSEC source: 0001493152-22-021919 · ownership.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,954 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.80 to $24.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 6,943 | $1.74 | $12,080.82 |
DisclosureSEC source: 0001493152-22-021919 · ownership.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 58,000 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001493152-21-031754 · ownership.xml · derivative · entry 1 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 58,000 shares Expires 2031-12-13 F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on January 14, 2022. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 18:28 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 180,800 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001104659-21-088374 · tm2121189-1_4seq1.xml · derivative · entry 3 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,800 Underlying: Common Stock · 180,800 shares Expires 2031-06-28 F5 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on July 29, 2021. Read SEC document |
| April 02, 2021 Filed Jul 1, 2021 18:28 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 328,921 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-21-088374 · tm2121189-1_4seq1.xml · derivative · entry 2 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,921 Underlying: Common Stock · 328,921 shares Expires 2031-04-01 F1 · derivative.exercise_price: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F4 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on July 4, 2021. F1 · derivative.underlying_shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F1 · balance_after: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. Read SEC document |
| April 02, 2021 Filed Jul 1, 2021 18:28 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 48,882 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-21-088374 · tm2121189-1_4seq1.xml · derivative · entry 1 Dake Benjamin T · CIK 0001869248 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,882 Underlying: Common Stock · 48,882 shares Expires 2031-04-01 F1 · derivative.exercise_price: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F3 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vested on May 2, 2021. F1 · derivative.underlying_shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F1 · balance_after: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.